| Name | Title | Contact Details |
|---|
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Lawnwood Regional Medical Center & Heart Institute is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Medco is a leading pharmacy benefit manager (PBM), with the nation's largest mail order pharmacy operations. Medco Pharmacy operates 10 mail-order pharmacies and partners with a nationwide network of approximately 60,000 retail pharmacies. Medco’s automated pharmacies located in Las Vegas, Indianapolis, and Willingboro, NJ, together have the capacity to fill more than 3 million prescriptions per week. Medco Health Solutions, Inc. is an American Pharmacy Benefits Management (PBM) company currently serving the needs of more than 65 million people. Medco provides pharmacy services for private and public employers, health plans, labor unions, government agencies, and individuals served by Medicare Part D Prescription Drug Plans. Medco is a member of the S&P 500 and is ranked number 34 on the 2011 Fortune 500 list, with 2011 revenues of more than $70 billion. It has earned the No. 1 ranking in the Healthcare: Pharmacy and Other Services category on Fortune magazine’s World’s Most Admired Companies list for five consecutive years (2008-2012). Medco was originally founded as National Pharmacies in 1983. In 1984, after an IPO, National Pharmacies became Medco Containment Services, LLC. In 1990, Medco Containment was acquired by Merck & Co., Inc. and became Merck-Medco. In August 2003, Medco Health Solutions, Inc. became an independent company in one of the largest domestic spin-offs at the time. It has recently been acquired by Express Scripts
MMS Holdings Inc is a Canton, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Haven Home Health is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.